This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pirker, R. Articles by Vansteenkiste, J. F. Search for Related Content PubMed PubMed Citation Articles by Pirker, R. Articles by Vansteenkiste, J. F. Social Bookmarking                            What's this?

Safety and Efficacy of Darbepoetin Alfa in Previously Untreated Extensive-Stage Small-Cell Lung Cancer Treated With Platinum Plus Etoposide

Robert Pirker, Rodryg A. Ramlau, Wolfgang Schuette, Petr Zatloukal, Irene Ferreira, Tom Lillie, Johan F. Vansteenkiste

From the Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria; Regional Lung Disease Centre, Oncology Department, Poznan, Poland; City Hospital Martha-Maria Halle Doelau, Second Medical Department, Halle, Germany; Department of Pneumology and Thoracic Surgery, Third Faculty of Medicine, Charles University, Faculty Hospital Bulovka, and Postgraduate Medical Institute, Prague, Czech Republic; Respiratory Oncology Unit, Department of Pulmonology, University Hospital Gasthuisberg, Leuven, Belgium; Amgen Limited, Cambridge, United Kingdom; and Amgen Inc, Thousand Oaks, CA

Corresponding author: Robert Pirker, MD, Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria; e-mail: robert.pirker{at}meduniwien.ac.at

Purpose A placebo-controlled, double-blind, randomized, phase III study was conducted in patients with extensive-stage small-cell lung cancer receiving first-line platinum-containing chemotherapy to determine if increasing or maintaining hemoglobin concentration with darbepoetin alfa could increase patient survival.

Patients and Methods Darbepoetin alfa (300 µg) or placebo was administered once per week for 4 weeks then every 3 weeks for up to six cycles of chemotherapy (carboplatin plus etoposide or cisplatin plus etoposide) plus 3 weeks after the last dose of chemotherapy. Patients with disease progression were observed until death or until all patients completed their end-of-study visit and 496 deaths had occurred. The two coprimary end points were change in hemoglobin concentration from baseline to the end of the chemotherapy period and overall survival; statistical testing of survival was done if change in hemoglobin was significant at P < .05.

Results The study enrolled 600 patients. Patients' hemoglobin levels dropped due to the myelosuppressive chemotherapy; however, treatment with darbepoetin alfa maintained hemoglobin levels significantly higher than placebo (P < .001). There was no statistically significant difference in overall survival between the treatment groups (hazard ratio [HR], 0.93; 95% CI, 0.78 to 1.11; P = .431). As expected, darbepoetin alfa was associated with a higher incidence of thromboembolic events (darbepoetin alfa, 9%; placebo, 5%). The transfusion risk was lower in the darbepoetin versus placebo group (HR, 0.40; 95% CI, 0.29 to 0.55).

Conclusion The results of this study did not demonstrate improved survival after treatment with darbepoetin alfa; however, they reinforce the benefit of erythropoiesis-stimulating agents in reducing transfusions and their neutral impact on survival in patients with chemotherapy-induced anemia.

Supported by Amgen Inc (study No. 20010145; ClinicalTrials.gov ID: NCT00119613 [ClinicalTrials.gov] ).

Presented in part at the 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				N. Skoetz, O. Weingart, I. Monsef, K. Bauer, C. Brillant, C. Herbst, S. Kluge, and A. Engert Ninth Biannual Report of the Cochrane Haematological Malignancies Group--Focus on Hematopoietic Growth Factors J Natl Cancer Inst, May 6, 2009; 101(9): E1 - E1. [Full Text]